Valuation : Outlook Therapeutics, Inc.

Market Cap 162M 140M 131M 120M 224M 15.32B 225M 1.55B 602M 7.86B 609M 596M 25.32B P/E 2026 *
-1.15x
P/E 2027 * -2.82x
Enterprise Value 162M 140M 131M 120M 224M 15.32B 225M 1.55B 602M 7.86B 609M 596M 25.32B EV / Sales 2026 *
197x
EV / Sales 2027 * 3.9x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day+2.70%
1 week+3.35%
Current month+5.23%
1 month-35.29%
3 months-14.19%
6 months+54.35%
Current year-57.82%
1 week 0.6
Extreme 0.6043
0.7
1 month 0.59
Extreme 0.59
1.18
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
55.6
10 years 0.16
Extreme 0.1611
867.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Director of Finance/CFO 59 2026-08-31
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Director/Board Member 50 2017-10-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

500,000 0.2060%
8/14/26 Buy

Chief Executive Officer

202,020 0.0832%
8/14/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
+2.70%+3.35%-28.72%-85.51% 162M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.56%+0.82%+62.63%+87.95% 27.52B
Weighted average by Cap. -1.03%+0.11%+89.35%+127.79%

Financials

2026 *2027 *
Net sales 824K 709K 667K 609K 1.14M 77.8M 1.14M 7.88M 3.06M 39.92M 3.09M 3.03M 129M 41.57M 35.77M 33.66M 30.74M 57.51M 3.92B 57.67M 398M 154M 2.01B 156M 153M 6.49B
Net income -62.6M -53.87M -50.68M -46.3M -86.61M -5.91B -86.84M -599M -232M -3.03B -235M -230M -9.77B -36.77M -31.64M -29.77M -27.19M -50.87M -3.47B -51.01M -352M -136M -1.78B -138M -135M -5.74B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-09-04 US$0.6665 +2.70% 6,395,728
26-09-03 US$0.6490 +3.62% 6,640,789
26-09-02 US$0.6263 +0.51% 4,607,303
26-09-01 US$0.6231 -1.63% 3,579,939
26-08-31 US$0.6334 -1.78% 6,431,455
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6665USD
Average target price
4.900USD
Spread / Average Target
+635.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock